Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.…
Sensus Healthcare (SRTS) Q3 2026 Earnings Call Transcript
Sensus Healthcare (NASDAQ: SRTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 2.260 USD on 20 November 2026, down 35.8% over 52 weeks. Its 52-week range is 2.140 USD to 5.490 USD: the price is 58.8% below the high and 5.6% above the low.
Its market capitalisation is 37.20M USD.
Sensus Healthcare reports return on equity of -16.0%, an operating margin of -74.0% and revenue down 12.9% year over year.
It holds more cash than debt, a net cash position of 12.64M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 5.250 USD is 132.3% above the current price. The next earnings report is expected on 11 February 2027.